Immunotherapy with chemotherapy for MSI-H stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy medicine (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for people with a specific type of stomach cancer (MSI-H/dMMR) that can be removed by surgery. The goal is to see if this combination helps shrink the tumor and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with adenocarcinoma of the stomach or where the stomach meets the esophagus.
- Your cancer has a specific genetic feature called MSI-H or dMMR (doctors can test for this).
- Your doctor believes the cancer can be removed with surgery (it hasn’t spread beyond the area).
- You are able to swallow pills and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well immunotherapy (drugs that boost your immune system to fight cancer) works before surgery for stomach cancer that has a specific genetic marker (dMMR or MSI-H). It aims to find factors that predict response, which may lead to more personalized and effective treatment.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which blocks blood vessel growth to tumors), and chemotherapy for people with a specific type of stomach cancer that is MSI-H/dMMR (meaning it has many mutations and may respond better to immunotherapy). The goal is to shrink the cancer and potentially make it removable by surgery.
This clinical trial tests whether adding an immunotherapy drug called tislelizumab to chemotherapy before surgery is better than chemotherapy alone for people with a certain type of stomach cancer. The goal is to see if the combination helps shrink the tumor and improves the chance of successful surgery.
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.